Amid Brexit Chaos, UK Defers Life Sciences Spending Commitments
Sector wants R&D tax credits updated, investment in Biomedical Catalyst, and is dismayed by spending delay.
You may also be interested in...
Podcast: Living In China's Coronavirus Lockdown; Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches
Keytruda is set to remain dominant despite knockback, though Tecentriq could claim prized NSCLC adjuvant approval first
As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.